Dr. Richard S. Blumberg trained in internal medicine (The New York Hospital, 1982), infectious diseases (Massachusetts General Hospital, 1986) and gastroenterology and hepatology (Brigham and Women’s Hospital 1989).
He is currently Senior Physician in Medicine and Gastroenterology at Brigham and Women’s Hospital (BWH) where he holds the position of Division Chief of Gastroenterology, Hepatology and Endoscopy, is Professor of Medicine at Harvard Medical School, co-Director of the Harvard Digestive Diseases Center and past-Director of the Brigham Research Institute. In addition, Dr. Blumberg serves on the Executive Advisory Committee of the Department of Medicine and Gastrointestinal Mucosal Pathobiology Study Section (NIDDK) and has served as a member of the Immunology Sciences Study Section of the NIAID, a member on the National Commission of Digestive Diseases of the NIDDK, scientific consultant to the Human Microbiome Project (NHGRI), a member of the Vaccine Branch External Advisory Board (NCI), Chair of the External Scientific Consultants for the Intestinal Stem Cell Consortium Initiative (NIDDK), and a member of the Board of Scientific of Scientific Councilors (NIAID).
Dr. Blumberg has served as the Chair of the National Scientific Advisory Committee of the Crohn’s and Colitis of America (2002-2005) and was former President of the Society for Mucosal Immunology (2007-2009). Dr. Blumberg is an elected member of the American Association of Clinical Investigation and the Association of American Physicians and the recipient of a MERIT award from the NIH (2005), the William Beaumont Prize from the American Gastroenterological Association (2012), the Distinguished Scientific Achievement Award from the Crohn’s and Colitis Foundation of America (2012), a Lifetime Achievement Award from the Society of Mucosal Immunology (2015) and the Lloyd Mayer Award in Mucosal Immunology (2016). He has been an NIH funded investigator since 1989 whose research program focuses on mucosal immunology. He was the Scientific Founder of Syntonix Pharmaceuticals that developed long acting therapeutic agents recently approved by the FDA and EMA for the treatment of hemophilia and is the Scientific Founder of Syntimmune Inc which is currently developing therapeutic agents that target FcRn. His long standing research interests focus on the immune functions of CD1d-NKT cells, the unfolded protein response, CEACAM1 and FcRn.